Revolution Medicines Reports Highly Positive Phase 3 Daraxonrasib Results in Pancreatic Cancer
RVMD has more than doubled off its 52-week low of $29.98.
Summary
Revolution Medicines announced statistically significant and clinically meaningful improvements in progression-free and overall survival from its Phase 3 trial of daraxonrasib for metastatic pancreatic cancer, with plans for immediate regulatory submission.
Key Events · Product Development and Regulatory · RVMD
-
Positive Phase 3 Trial Results
Daraxonrasib demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma.
-
Significant Overall Survival Benefit
The drug achieved a median overall survival of 13.2 months, compared to 6.7 months for standard of care chemotherapy, with a hazard ratio of 0.40 (p < 0.0001).
-
Favorable Safety Profile
Daraxonrasib was generally well tolerated, exhibiting a manageable safety profile with no new safety signals observed.
-
Expedited Regulatory Pathway Planned
The company intends to submit these final data to global regulatory authorities, including a New Drug Application to the U.S. FDA with a Commissioner's National Priority Voucher.
Analysis · RVMD · Life Sciences
This 8-K officially confirms and provides detailed results for the highly positive topline data from the Phase 3 RASolute 302 clinical trial for daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The drug demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS), notably doubling the median OS to 13.2 months compared to 6.7 months for standard of care chemotherapy. The favorable safety profile further strengthens the drug's profile. These robust efficacy and safety data represent a major de-risking event for Revolution Medicines' lead oncology candidate and significantly enhance its commercial potential. The company's intent to submit a New Drug Application with a Commissioner's National Priority Voucher suggests an expedited regulatory pathway. This news is a substantial positive catalyst, reinforcing the company's pipeline value and potentially driving the stock higher, especially as it is already trading near its 52-week high.
At the time of this filing, RVMD was trading at $131.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.1B. The 52-week trading range was $29.98 to $124.49. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.